| Date Filed | Type | Description |
| 04/27/2021 |
GN
| Galectin Therapeutics to Present at 4th Global NASH Congress |
| 04/06/2021 |
GN
| Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study |
| 03/31/2021 |
GN
| Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update |
| 03/08/2021 |
GN
| OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics' Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy |
| 12/11/2020 |
GN
| Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020 |
| 11/09/2020 |
GN
| Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 |
| 09/29/2020 |
GN
| Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today |
| 09/22/2020 |
GN
| Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 |
| 09/02/2020 |
GN
| Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer |
| 06/30/2020 |
GN
| UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis |
| 06/30/2020 |
GN
| Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis |
| 05/11/2020 |
GN
| Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update |
| 04/02/2020 |
GN
| Galectin Therapeutics Update on the Impact of COVID-19 |
| 03/16/2020 |
GN
| Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update |
| 12/05/2019 |
GN
| Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis |
| 11/18/2019 |
GN
| Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit |
| 11/11/2019 |
GN
| Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis |
| 05/28/2019 |
GN
| Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise |
| 05/23/2019 |
GN
| Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering |
| 05/10/2019 |
GN
| Galectin Therapeutics Releases Richard E. Uihlein's Open Letter to Stockholders Dated May 10, 2019 |
| 05/10/2019 |
GN
| Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update |
| 04/15/2019 |
GN
| Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement |
| 03/22/2019 |
GN
| Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology |
| 03/06/2019 |
GN
| Galectin Therapeutics Releases Richard E. Uihlein's Open Letter to Stockholders |